Creatine Kinase-MB (CK-MB)
Creatine Kinase-MB (CK-MB) is released from damaged cardiac tissue 2-6 hours following infarction. CK-MB values peak 12-24 hours after infarction and return to normal within 24-48 hours. Certain diseases of skeletal muscle result in an increased amount of CK-MB. The various causes of rhabdomyolysis, including the muscular dystrophies, commonly result in an abnormal increase in serum CK-MB activity. Swiss-Prot Accession Number: Brain P12277; Muscle P06732.
Swiss-Prot Accession Number: P12277, P06732
Product AssociationsThis analyte is not currently part of Myriad RBM's testing menu.
PublicationsBiomarkers of Community-Acquired Pneumonia: A Key to Disease Diagnosis and Management (2019) Savvateeva EN, Rubina AY, Gryadunov DA BioMed Research International
Blood-based protein mediators of senility with replications across biofluids (2019) Royall DR, Palmer RF, The Alzheimer's Disease Neuroimaging Initiative Brain Communications
Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment (2018) van den Ham HJ, Cooper J, Tomasik J, Bahn S, Aerts J, Oseterhaus A, Gruters R, Andeweg A PLoS One
Serum Apolipoprotein E and Other Inflammatory Markers Can Identify Non-Responding Patients to a Dendritic Cell Vaccine (2018) Leeman H, Kaminska E, Green D, Bodman-Smith M, Gravett A, Bodman-Smith K, Copier J, Coulton G, Fusi A, Dalgleish AG Translational Oncology
Effects of Acute Endurance Exercise on Plasma Protein Profiles of Endurance-Trained and Untrained Individuals over Time (2016) Schild M, Eichner G, Beiter T, Zuegel M, Niess AM, Steinacker JM, Mooren FC Mediators of Inflammation
Variation in Serum Biomarkers with Sex and Female Hormonal Status: Implications for Clinical Tests (2016) Ramsey JM, Cooper JD, Penninx BWJH, Bahn S Scientific Reports
A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis (2015) Pardanani A, Tefferi A, Jamieson C, Gabrail NY, Lebedinsky C, Gao G, Liu F, Xu C, Cao H and Talpaz M Blood Cancer Journal
Identification of a molecular profile associated with immune status in first onset schizophrenia patients (2013) Herberth M, Rahmoune H, Schwarz E, Koethe D, Harris LW, Kranaster L, Witt SH, Spain M, Barnes A, Schmolz M, Leweke MF, Guest PC, Bahn S Clin Schizophr Relat Psychoses
Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients (2012) Schwarz E, Guest PC, Steiner J, Bogerts B, Bahn S Translational Psychiatry (2012) 2, e82
A Serum Protein-Based Algorithm for the Detection of Alzheimer Disease (2010) O'Bryant SE, Xiao G, Barber R, Reisch J, Doody R, Fairchild T, Adams P, Waring S, Diaz-Arrastia R; for the Texas Alzheimer's Research Consortium Arch Neurol 67: 1077-1081.
Dysregulated macrophage-inflammatory protein-2 expression drives illness in bacterial superinfection of influenza. (2010) Zavitz CC, Bauer CM, Gaschler GJ, Fraser KM, Strieter RM, Hogaboam CM, Stampfli MR J Immunol 184: 2001-2013.
Regression of Human Pancreatic Tumor Xenografts in Mice After a Single Systemic Injection of Recombinant Vaccinia Virus GLV-1h68. (2009) Yu YA, Galanis C, Woo Y, Chen N, Zhang Q, Fong Y, Szalay AA Mol Cancer Ther 8: 141-151.